课题基金 / 基金详情

项目摘要

项目成果

JAMES L MOHLER的其他基金

相似基金

相关文献

中文摘要
翻译
项目1促成了两项改变范式的发现。首先,雄激素受体(AR)通路似乎对去势-复发性前列腺癌(CAP)的生长至关重要,尽管去势后循环中的睾丸雄激素水平很高。其次,去势-复发性CAP会产生高水平的组织睾酮(T)和双氢睾酮(DHT),这是AR的首选配体。内分泌产生的睾丸雄激素为新的治疗提供了一个靶点。进一步的进展可能来自于应用新的治疗方法来治疗与雄激素剥夺疗法(ADT)同时进行的CAP,当CAP细胞死亡最大且存活的细胞处于最大压力下时。这些研究的中心假设是,CAP可以通过联合攻击内分泌雄激素代谢和AR来治愈或缓解,同时消除循环中的睾丸雄激素(内科或外科去势)。为了验证这一假设,并允许在晚期CAP中进行适当的临床试验,将在去势后立即使用临床前模型评估ADT的反应。一般而言,单元格或 组织采样将在去势前以及去势后12小时、1、2、4、8、16和30天进行。去势对雄激素轴的影响将在体外4个水平和体内6个水平进行评估。在体外和体内的4个水平的评估将包括:1)用qRT-PCR在信使核糖核酸水平上改变雄激素代谢酶,用免疫组织化学法(IHC)在蛋白质水平上改变;2)用LC-MS法测定雄激素水平;3)用IHC方法调节PSA、Nkx3.1和HK2的雄激素基因表达;4)细胞生长。体内测量将包括进展时间和存活率。将使用雄激素敏感的CWR22细胞悬液、雄激素依赖的CWR22异种移植和新鲜手术组织异种移植模型来研究ADT后的雄激素代谢。ADT后对生存至关重要的雄激素代谢的变化将在体外使用shRNA或药物以及在体内使用慢病毒shRNA和/或药物作为靶点(目标1)。由肾上腺雄激素的内分泌代谢形成的睾丸雄激素将使用53-还原酶或使用慢病毒感染传递的Sult2A1来清除(目标2)。最后,将使用慢病毒AR shRNA构建或AR降解小分子来去除AR(目标3)。
英文摘要
Project 1 has contributed to two paradigm changing discoveries. First, the androgen receptor (AR) pathway appears critical to the growth of castration-recurrent prostate cancer (CaP) in spite of castrate levels of circulating testicular androgens. Second, castration-recurrent CaP produces high tissue levels of testosterone (T) and dihydrotestosterone (DHT), the preferred AR ligand. Intracrine-produced testicular androgens present a target for novel therapies. Further advances may result from applying novel treatments to CaP coincidental with androgen deprivation therapy (ADT) when CaP cell death is at a maximum and surviving cells are under greatest stress. The central hypothesis of the proposed studies is that CaP can be cured or remission extended by a coordinated attack upon intracrine androgen metabolism and AR coincidental with elimination of circulating testicular androgens (medical or surgical castration). In order to test this hypothesis and allow the formulation of an appropriate clinical trial in advanced CaP, the response to ADT will be assessed using preclinical models in the immediate post-castration period. In general, cell or tissue sampling will be conducted just prior to castration and 12h and 1, 2, 4, 8, 16 and 30d after "castration." The effect of castration upon the androgen axis will be assessed on 4 levels in vitro and 6 levels in vivo. The 4 levels of assessment in vitro and in vivo will include 1) changes in androgen metabolism enzymes at the mRNA level using qRT-PCR and protein level using immunohistochemistry (IHC); 2) androgen levels using LC-MS; 3) androgen-regulated gene expression using IHC for PSA, Nkx3.1 and hK2; and 4) cell growth. Measures in vivo will include 5) time to progression and 6) survival. Androgen metabolism after ADT will be studied using androgen-sensitive CWR22 cell suspensions, the androgen-dependent CWR22 xenograft and a fresh surgical tissue xenograft model. Changes in androgen metabolism critical for survival after ADT will be targeted using shRNA or drug in vitro and lentiviral shRNA and/or drug in vivo (Aim 1). Testicular androgens formed by intracrine metabolism of adrenal androgens will be removed using 53-reductase or Sult2A1 delivered using lentiviral infection (Aim 2). Finally, AR will be removed using lentiviral AR shRNA constructs or AR degrading small molecules (Aim 3).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ImmunoAnalysis and Research Specimen Management
ImmunoAnalysis and Research Specimen Management
Interference with Androgen Receptor and Its Ligands
CORE B
海外基金